TriCor is a brand name of fenofibrate, approved by the FDA in the following formulation(s):
TRICOR (fenofibrate - tablet; oral)
Manufacturer: ABBOTT LABS PHARM
Approval date: November 5, 2004
Strength(s): 145MG [RLD][AB], 48MG [AB]
Has a generic version of TriCor been approved?
A generic version of TriCor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to TriCor and have been approved by the FDA:
fenofibrate tablet; oral
Manufacturer: LUPIN LTD
Approval date: December 23, 2011
Strength(s): 145MG [AB], 48MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of TriCor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Patent 6,074,670
Issued: June 13, 2000
Inventor(s): Stamm; Andre & Seth; Pawan
Assignee(s): Laboratoires Fournier, S.A.
The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 .mu.m, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layers(s). The invention also provides a method for preparing said composition.Patent expiration dates:
- January 9, 2018
- January 9, 2018
Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Patent 6,277,405
Issued: August 21, 2001
Inventor(s): Stamm; Andre & Seth; Pawan
Assignee(s): Labaratoires Fournier, S.A.
The invention provides a micronized fenofibrate composition. The micronized fenofibrate composition has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or with 0.025M sodium lauryl sulfate. The composition can further comprise hydrophilic polymers, surfactants, hydrosoluble carriers, outer phases or layers, or other pharmaceutically acceptable excipients. The immediate-release fenofibrate composition is preferably in the form of a tablet or in the form of granules inside a capsule.Patent expiration dates:
- January 9, 2018
- January 9, 2018✓
- January 9, 2018
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
Patent 6,375,986
Issued: April 23, 2002
Inventor(s): Niels P.; Ryde & Stephen B.; Ruddy
Assignee(s): Elan Pharma International Ltd.
Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.Patent expiration dates:
- September 21, 2020✓✓
- September 21, 2020
Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Patent 6,589,552
Issued: July 8, 2003
Inventor(s): André ; Stamm & Pawan; Seth
Assignee(s): Laboratoires Fournier, S.A.
The invention provides fenofibrate compositions comprising granulates. The granulates can comprise micronized fenofibrate, inert hydrosoluble carrier particles, hydrophilic polymers, and, optionally, surfactants.Patent expiration dates:
- January 9, 2018
- January 9, 2018
Fenofibrate pharmaceutical composition having high bioavailability
Patent 6,652,881
Issued: November 25, 2003
Inventor(s): André ; Stamm & Pawan; Seth
Assignee(s): Laboratories Fournier, S.A.
The invention provides compositions comprising micronized fenofibrate, where the compositions have a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.Patent expiration dates:
- January 9, 2018✓
- January 9, 2018✓
- January 9, 2018
Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Patent 7,037,529
Issued: May 2, 2006
Inventor(s): Stamm; André & Seth; Pawan
Assignee(s): Laboratoires Fournier
The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 μm, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layer(s). The invention also provides a method for preparing said composition.Patent expiration dates:
- January 9, 2018✓
- January 9, 2018
Fenofibrate pharmaceutical composition having high bioavailabilty
Patent 7,041,319
Issued: May 9, 2006
Inventor(s): Stamm; André & Seth; Pawan
Assignee(s): Laboratoires Fournier
The invention provides fenofibrate tablets comprising granulates, wherein the granulates can comprise carrier particles, micronized fenofibrate, and at least one hydrophilic polymer.Patent expiration dates:
- January 9, 2018✓
- January 9, 2018
Nanoparticulate fibrate formulations
Patent 7,276,249
Issued: October 2, 2007
Inventor(s): Ryde; Tuula & Gustow; Evan E. & Ruddy; Stephen B. & Jain; Rajeev & Patel; Rakesh & Wilkins; Michael John
Assignee(s): Elan Pharma International, Ltd.
Fournier Laboratories Ireland Ltd.
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Patent expiration dates:
- February 21, 2023✓
- February 21, 2023
Methods of treatment using nanoparticulate fenofibrate compositions
Patent 7,320,802
Issued: January 22, 2008
Inventor(s): Ryde; Tuula & Gustow; Evan E. & Ruddy; Stephen B. & Jain; Rajeev & Patel; Rakesh & Wilkins; Michael John
Assignee(s): Elan Pharma International, Ltd.
Fournier Laboratories Ireland Ltd.
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Patent expiration dates:
- February 21, 2023✓
- February 21, 2023
See also...
- Tricor Consumer Information (Drugs.com)
- Tricor Consumer Information (Wolters Kluwer)
- TriCor Consumer Information (Cerner Multum)
- Tricor Advanced Consumer Information (Micromedex)
- Fenofibrate Consumer Information (Drugs.com)
- CIP - Fenofibrate Consumer Information (Wolters Kluwer)
- Fenofibrate Consumer Information (Wolters Kluwer)
- Fenofibrate Consumer Information (Cerner Multum)
- Fenofibrate Advanced Consumer Information (Micromedex)
- Fenofibrate AHFS DI Monographs (ASHP)
No comments:
Post a Comment